buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
All listed companies/Piramal Pharma Limited
03 /Listed universe · Healthcare · CDMO

Piramal Pharma Limited.

Value itCompareScreener.in ↗Tijori ↗NSE ↗BSE ↗
Snapshot

Healthcare · CDMO

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.

Market cap
₹27,978 cr
P/E (TTM)
0
P/B (latest)
3.4
ROE (TTM)
0%
ROCE (TTM)
2.4%
Sales CAGR 3y
7.8%
PAT CAGR 3y
20.5%
Debt / equity
0.67x
Promoter
34.8%
Dividend yield
—
Size
Small
Codes
PPLPHARMA · 543635
Price

₹209.07 · 29 Sept 2026

1M
−4.4%
3M
+25.4%
6M
+45.6%
YTD
+23.1%
1Y
+9.1%
3Y
+115.6%
5Y
—
vs 52w high
−7.7%

52-week ₹133.27 – ₹226.62 · ADTV ₹111.7 cr · price-only.

Trend

Sales and net profit by fiscal year, ₹ crore

Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ